Ignite Creation Date:
2024-05-05 @ 9:16 PM
Last Modification Date:
2024-10-26 @ 10:02 AM
Study NCT ID:
NCT00851955
Status:
COMPLETED
Last Update Posted:
2016-01-12
First Post:
2009-02-25
Brief Title:
Role of CXCR2 LigandsCXCR2 Biological Axis in Pancreatic Cancer
Sponsor:
Mayo Clinic
Organization:
Mayo Clinic
Study Overview
Official Title:
Role of CXCR2 LigandsCXCR2 Biological Axis in Pancreatic Cancer
Status:
COMPLETED
Status Verified Date:
2016-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The investigators hypothesize that the CXCR2 ligandsCXCR2 biological axis plays an important role in promoting angiogenesis in PC and that the genetic changes and the microenvironment of the tumor regulate the expression of CXCR2 ligandsCXCR2 in PC in order to potentiate their angiogenic phenotype A corollary of this hypothesis is that the cell surface receptors CXCR2 and the intracellular signaling pathways that mediate the angiogenic responses induced by ELR CXC-chemokines are potential targets for novel therapeutic interventions in PC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None